Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study

Archives of Medical Science

Volumn 7, Issue 5, 2011, Pages 796-805

  Athyros, Vassilios G ^a   Giouleme, Olga ^a   Ganotakis, Emmanouel S ^b   Elisaf, Moses ^c   Tziomalos, Konstantinos ^b   Vassiliadis, Themistoklis ^b   Liberopoulos, Evangelos N ^d   Theocharidou, Eleni ^d   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Atorvastatin; Cardiovascular disease; Metabolic syndrome; Multifactorial treatment; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; QUINAPRIL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DIURETIC THERAPY; DRUG DOSE TITRATION; DYSLIPIDEMIA; EXERCISE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FUNCTION TEST; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 81555203011     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.25554     Document Type: Article

References (57)

1. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-9.
2. Fatani S, Itua I, Clark P, Wong C, Naderali EK. The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. Int J Gen Med 2011; 4: 211-9.
3. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011 Jun 17. doi: 10.1002/hep.24491. [Epub ahead of print].
4. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57. (Pubitemid 34533559)
5. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-9.
6. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994; 20: 1442-9. (Pubitemid 24359054)
7. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52. (Pubitemid 40911310)
8. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721-8.
9. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9. (Pubitemid 32893993)
10. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16. (Pubitemid 35403784)
11. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Am J Epidemiol 1998; 148: 958-66. (Pubitemid 28533735)
12. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
13. Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
14. Athyros VG, Ganotakis E, Kolovou G, et al.; for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT). A prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011 (in press PMID: 21476961).
15. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52. (Pubitemid 41532612)
16. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
17. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-21.
18. Estep M, Abawi M, Jarrar M, et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg 2011 Jul 9. DOI: 10.1007/s11695-011-0475-1 [Epub ahead of print].
19. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-6. (Pubitemid 43334347)
20. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009; 15: 479-89.
21. Tilg H, Moschen A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2010; 56: 159-67.
22. Duvnjak M, Tomasic V, Gomercic M, Smircic Duvnjak L, Barsic N, Lerotic I. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009; 60 Suppl 7: 57-66.
23. Comar KM, Sterling RK. Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006; 23: 207-15. (Pubitemid 43382029)
24. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-9. (Pubitemid 38241340)
25. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-54. (Pubitemid 38702666)
26. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65.
27. Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007; 56: 443-4. (Pubitemid 46579783)
28. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49: 80-6.
29. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 1997-2006. (Pubitemid 41803111)
30. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-37. (Pubitemid 47058108)
31. Ratziu V, Zelber-Sagi S. Pharmacologic therapy of nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13: 667-88.
32. Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010; 34: 1255-64.
33. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8. (Pubitemid 38938715)
34. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in non-alcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010; 52: 2206-15.
35. Caldwell SH, Argo CK, Al-Osaimi AM. Therapy of NAFLD: insulin sensitizing agents. J Clin Gastroenterol 2006; 40 (Suppl 1): S61-6. (Pubitemid 44309545)
36. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-3. (Pubitemid 38824162)
37. Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Adv Ther 2008; 25: 1141-74.
38. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5. (Pubitemid 39425579)
39. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 942-54.
40. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009; 54: 2290-5.
41. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83. (Pubitemid 43875555)
42. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for non-alcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther 2006; 24: 698-9. (Pubitemid 44127854)
43. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-41. (Pubitemid 46817693)
44. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-71.
45. Deedwania P, Barter P, Carmena R, et al.; the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919-28. (Pubitemid 44331360)
46. Pyorala K, Ballantyne CM, Gumbiner B, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004; 27: 1735-40. (Pubitemid 38857452)
47. Roglans N, Sanguino E, Peris C, et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructosefed rats. J Pharmacol Exp Ther 2002; 302: 232-9. (Pubitemid 34680443)
48. Mangaloglu L, Cheung RC, Van Iderstine SC, Taghibiglou C, Pontrelli L, Adeli K. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism 2002; 51: 409-18. (Pubitemid 34406553)
49. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care 2010; 33: 2266-70.
50. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011 Mar 10 [Epub ahead of print. PMID: 21388346].
51. Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 2011 Mar 21 [Epub ahead of print. PMID: 21427524].
52. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with nonalcoholic fatty liver disease: is there a link? J Hepatol 2011; 54: 1020-9.
53. Catalano D, Trovato GM, Martines GF, Pirri C, Trovato FM. Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int 2011 Jan 28 [Epub ahead of print. PMID: 21484130].
54. Athyros VG, Karagiannis A, Ganotakis ES, et al.; the ATTEMPT Collaborative Group. Improvement of renal function and serum uric acid levels by multifactorial intervention and their effects in clinical outcome in patients with multiple cardiovascular disease risk factors. A post hoc analysis of the ATTEMPT study. Curr Med Res Opinion 2011 doi:10.1185/03007995.2011.595782.
55. Athyros VG, Elisaf M, Alexandrides T, et al.; the ATTEMPT Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome. A post hoc ATTEMPT analysis. Angiology 2011, DOI: 10.1177/0003319711421341.
56. Martín-Castillo A, Castells MT, Adánez G, Polo MT, Pérez BG, Ayala I. Effect of atorvastatin and diet on nonalcoholic fatty liver disease activity score in hyperlipidemic chickens. Biomed Pharmacother 2010; 64: 275-81.
57. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for non-alcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther 2006; 24: 698-9. (Pubitemid 44127854)